ACRAF SpA (Gruppo Angelini)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ACRAF SpA (Gruppo Angelini)
Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.
The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.
Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital.
The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.